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Evaluation of Current Heparin Weight Based Protocol in Obese Patients
Abstract
Purpose: To evaluate the difference in achieving goal activated partial thromboplastin time (aPTT) within
24 hours utilizing the institutional heparin weight based protocol between obese and non-obese patients.
Methods: Retrospective, non-randomized, open label chart review in a community based hospital. Patients
age 18 years or older receiving heparin therapy for greater than or equal to 24 hours identified. Patients
were excluded if the protocol was utilized for acute coronary syndrome or interrupted within the initial
24 hours of therapy. Patients were also excluded if any deviations from the protocol were identified. The
primary endpoint evaluated the difference in achieving goal aPTT within 24 hours between obese and
non-obese patients. The secondary endpoint evaluated the difference in achieving goal aPTT within 24-48
hours and safety outcomes such as bleeds. Results: Of the 253 patients identified, 167 patients were
included and 86 patients were excluded. Seventy-two (71.3%) of the nonobese and 48 (72.7%) of obese
patients achieved goal aPTT within 24 hours (odd ratio [OR]: 0.98, 95 % confidence interval (CI): 0.6 to
1.58). Sixteen (15.8%) of nonobese and 13 (19.7%) of the obese patients achieved goal aPTT within 24 to
48 hours (OR: 0.77, 95 % CI: 0.3 to 1.95). Two (1.9 %) of the nonobese and 3 (4.5 %) of the obese patients
had a documented major bleed (OR: 0.42 and 95 % CI: 0.69 to 2.61). Conclusion: Overall, there was no
difference in achieving goal aPTT between nonobese and obese patients while utilizing our facility’s weight
based heparin dosing. No major bleeding was documented that warranted discontinuation of therapy, and
bleeding incidences between both groups were similar.
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ABSTRACT
Purpose: To evaluate the difference in achieving goal activated partial thromboplastin time (aPTT) within 24 hours utilizing the
institutional heparin weight based protocol between obese and non-obese patients. Methods: Retrospective, non-randomized,
open label chart review in a community based hospital. Patients age 18 years or older receiving heparin therapy for greater than
or equal to 24 hours identified. Patients were excluded if the protocol was utilized for acute coronary syndrome or interrupted
within the initial 24 hours of therapy. Patients were also excluded if any deviations from the protocol were identified. The primary
endpoint evaluated the difference in achieving goal aPTT within 24 hours between obese and non-obese patients. The
secondary endpoint evaluated the difference in achieving goal aPTT within 24-48 hours and safety outcomes such as bleeds.
Results: Of the 253 patients identified, 167 patients were included and 86 patients were excluded. Seventy-two (71.3%) of the
nonobese and 48 (72.7%) of obese patients achieved goal aPTT within 24 hours (odd ratio [OR]: 0.98, 95 % confidence interval
(CI): 0.6 to 1.58). Sixteen (15.8%) of nonobese and 13 (19.7%) of the obese patients achieved goal aPTT within 24 to 48 hours
(OR: 0.77, 95 % CI: 0.3 to 1.95). Two (1.9 %) of the nonobese and 3 (4.5 %) of the obese patients had a documented major
bleed (OR: 0.42 and 95 % CI: 0.69 to 2.61). Conclusion: Overall, there was no difference in achieving goal aPTT between
nonobese and obese patients while utilizing our facility’s weight based heparin dosing. No major bleeding was documented that
warranted discontinuation of therapy, and bleeding incidences between both groups were similar.
BACKGROUND
Unfractionated heparin (UFH) is an indirect factor Xa and IIa inhibitor within the clotting cascade, preventing the formation of
fibrin clots.1 Its anticoagulant effect is often unpredictable due to its large molecular weight (up to 30,000 Da), unique
pharmacological profile, and binding activity to plasma proteins.1 In order to overcome the unpredictable effect of UFH, though it
is labor intensive, activated partial thromboplastin time (aPTT) with a recommended goal between 1.5 to 2.5 times the baseline
has been used to determine the appropriateness of current therapy.1-3 Currently UFH has proven beneficial when preventing
thromboembolic disease, but its efficacy is dependent on appropriate dosing. Raschke et al performed a randomized controlled
trial that compared weight based UFH dosing with the standard nomogram.4 At 24 hours, 97% of participants in the weight-based
compared to 77% in the standard nomogram achieved goal aPTT.4
Higher plasma concentrations of prothrombotic factors have been identified in obese patients.5 Abdominal obesity has shown to
correlate with an increased mean platelet volume. This leads to increased adhesiveness and hyperaggregability, suggesting
higher risk for systemic thrombosis.6 In a retrospective setting, evaluating any potential effects of body mass index (BMI) on
aPTT levels in cardiac patients found no significant difference (p=0.5) in frequency of first aPTT level within range (60-90 secs).7
According to the 2012 American College of Chest Physician guidelines for treatment of venous thromboembolism,
recommendations for UFH therapy include an initial bolus dose of 80 units/kg followed by an initial infusion of 18 units/kg/hour;
this therapy helps target an aPTT level of 1.5 – 2.5 times the baseline aPTT.1,8,9 Currently, a universal UFH weight-based
nomogram does not exist and information on the dosing of UFH and efficiency of an UFH nomogram in obese patients is lacking.
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Although each hospital has adopted its own nomogram with a target aPTT level and dose titration based on the repeat measure
of aPTT levels, clinical data targeting if heparin weight-based nomogram would have the similar effects between obese and nonobese patients is limited. Spruill et al found no difference in time to target aPTT between nonobese and obese patients when
evaluating the need for different heparin dosing between the two groups.10
Our institutional heparin weight-based protocol for standard dosing utilizes a bolus of 65 units/kg (maximum 5,000 units) and an
initial infusion rate of 14 units/kg/hr (maximum 15 units/hour) with standardized dose adjustment based on repeat measures of
aPTT values. Standard dosing is utilized in patients with an indication other than acute coronary syndrome (ACS). These
indications include, but are not limited to, atrial fibrillation/flutter, deep vein thrombosis, pulmonary embolism, ischemic
stroke/transient ischemic attack, heart valve disorder, peripheral vascular disease, pulmonary hypertension, and
cardiomyopathy. Our facility adopted the more conservative approach from the 2012 ACCP guideline recommendation of
administering 60-70 units/kg (maximum 5,000 units) followed by an infusion of 12-15 units/kg/hr for safety purposes.1 An
inadequate UFH bolus and/or initial continuous infusion has been shown to delay reaching goal aPTT for > 24 hours in obese
(BMI ≥ 30 kg/m2) patients with venous thromboembolism.11 Our institution’s UFH dosing approach has not been rigorously
evaluated and conflicting data exist on achieving target aPTT between nonobese and obese patients.10,11 Therefore, this study is
designed to evaluate the difference in achieving goal aPTT within 24 hours between obese and non-obese patients with our
current heparin weight-based protocol.
METHODS
This retrospective, non-randomized, open label chart review was conducted at a large community base teaching hospital. Data
collection began after Institutional Review Board approval. The principal investigator performed all data collection. Patients were
identified through the institutional electronic medical records between August 1, 2011, and August 1, 2013, using the standard
UFH 25,000 units mixed in 250 mL of dextrose 5% (D5W) premix product. Information obtained from the institutional electronic
medical record were transferred to the data collection tool including demographic data, weight, height, indication for UFH,
appropriate management of protocol based on aPTT levels (time of each UFH bolus, rate change and time aPTT drawn),
pertinent lab values/tests and progress notes to assess major bleeding. The data were later transferred to a spreadsheet for
secured storage.
Eligible patients included those at least 18 years of age that utilized standard dosing heparin weight-based protocol for ≥ 24
hours. Exclusion criteria included those who utilized the protocol for ACS or if therapy was interrupted within the initial 24 hours.
Incorrect usage of the protocol such as omission of initial bolus dose and/or incorrect dose change based on aPTT level resulted
in exclusion of that patient.
The primary endpoint of this study evaluated the difference in achieving goal aPTT within 24 hours between obese and nonobese patients utilizing our institutional heparin weight-based protocol (Figure 1). Secondary endpoint evaluated the difference in
achieving goal aPTT within 24 to 48 hours between obese and non-obese patients. Based on the World Health Organization,
the non-obese patients were identified as those with a BMI < 30 kg/m 2 and obese patients with BMI ≥ 30 kg/m2.12 Goal aPTT
refers to achieving 1.5 to 2.5 times the baseline aPTT level determined by the photometric assay and BCS instrument. In
reference to our institutional protocol, goal aPTT is between 50-70 seconds. Safety endpoint according to the International
Society of Thrombosis and Haemostasis (ISTH) assessed major bleeding, any fatal bleeding, and/or symptomatic bleeding in a
critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial), and bleeding causing a fall
in hemoglobin level  2 g/dL and/or leading to transfusion of  2 units of whole blood or red cells.13
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Patient’s PTT
Initial dose
aPTT < 40s
aPTT, 40-49s
aPTT, 50-70s
aPTT, 71-85s
aPTT, 86-100s
aPTT, 100-150s

aPTT > 150s

3

Action
65 units/kg bolus (max 5,000 units), then 14
units/kg/hr (max 15 ml/hr)
65 units/kg bolus (max 5,000 units), add 2 ml to
current rate
20 units/kg bolus, add 1 ml to current rate
No change
Subtract 1 ml from current rate
Stop infusion for one hour and subtract 2 ml from
current rate
Stop infusion for two hours and subtract 3 ml from
current rate
Stop infusion for two hours
↓
If repeat aPTT less than 150, subtract 4 ml from
current rate
If repeat aPTT greater than 150, call physician and
continue to hold infusion
Figure 1: Weight-Based Nomogram

Order aPTT
6 hours after starting heparin
6 hours after bolus
6 hours after bolus/rate change
In 12 hours
6 hours after rate change
6 hours after rate change
6 hours after rate change
STAT aPTT 2 hours after infusion
stopped
↓
Repeat aPTT 6 hours after rate change

Statistical analysis
A sample size of 150 patients was needed to detect an estimated observed effect size of 0.5 between the two study groups, with
an α of 0.05, a β of 0.2 and a possible 5% dropout rate. Endpoints were evaluated for the per-protocol population. Statistical
evaluation comparing non-parametric and parametric data was accomplished with chi-squared and two sample t-test,
respectively. All non-parametric data was analyzed and expressed as an odds ratio (OR) with 95% confidence interval (CI).
Continuous data was analyzed and presented as descriptive statistics (mean ± standard deviation). All statistical analysis was
analyzed via Number Cruncher Statistical System (NCSS) software. A p-value < 0.05 was considered statistically significant.
RESULTS
During the study period, 253 patients were identified based on the utilization of the standard UFH 25,000 units/D5W 250ml
premix product. Patient selection is depicted in Figure 2. Based on the study criteria, 167 patients were included and 86 patients
were excluded. Of the 167 patients included in the analysis, 101 were in the nonobese and 66 were in the obese group. Baseline
characteristics are summarized in Table 1. Except for BMI, the patient characteristics between the two groups did not differ
significantly in age, height, and sex.

Group (kg/m2)
Age (years) a
Female
Male
Height (cm)a
Indications
DVT
PE
Atrial fibrillation
Valve disorder
PVD
Othersb

Table 1. Baseline Patient Characteristics
BMI < 30
BMI  30
n= 101 (%)
n= 66 (%)
64 ± 20
58 ± 15
n = 43 (42%)
n = 35 (53%)
n = 58 (57%)
n = 31 (47%)
170 ± 11
168 ± 13
23
22
20
11
4
21

aResults

14
18
19
8
3
4

are presented as mean ± standard deviation
indications include cardiomyopathy, hypercoagulable state and ischemic stroke
Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Peripheral Vascular Disease (PVD)
bOther
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Figure 2: Patient Selection
Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Peripheral Vascular Disease (PVD)
aOther indications include cardiomyopathy, hypercoagulable state and ischemic stroke
For the primary endpoint, 72 (71.3 %) of the nonobese and 48 (72.7 %) of obese patients achieved goal aPTT within 24 hours
(OR: 0.98 and 95 % CI: 0.6 to 1.58) (Figure 3) (Table 2). Patients who did not achieve goal aPTT within 24 hours were analyzed
for the secondary endpoint of achieving goal aPTT within 24 to 48 hours. The results showed 16 (15.8%) of non-obese and 13
(19.7%) of obese patients achieved goal aPTT of 50 to 70 seconds within 24 to 48 hours (OR: 0.77 and 95 % CI: 0.3 to 1.95)
(Table 2). Approximately 90 % of patients in both groups achieved goal aPTT within 48 hours (Figure 4).
Table 2. Study Endpoint
BMI < 30
BMI ≥ 30
n= 101 (%)
n= 66 (%)
Achieved Goal aPTT Within
24 Hours

72 (71.3)

48 (72.7)

Odds Ratio
95% Confidence Interval
OR: 0.98
95 % CI: 0.6 to 1.58

Achieved Goal aPTT Within
24-48 Hours

16 (15.8)

13 (19.7)

OR: 0.77
95 % CI: 0.3 to 1.95

Major Bleeding

2 (1.9)

3 (4.5)

OR: 0.42
95 % CI: 0.69 to 2.61

When evaluating the safety endpoint during the course of UFH therapy, two (1.9 %) of the 101 nonobese and three (4.5 %) of the
66 obese patients had a documented major bleed during the specified hospitalization (OR: 0.42 and 95 % CI: 0.69 to 2.61)
(Table 2). All five of the patients were categorically determined to experience major bleeding due to a ≥ 2 g/dL drop in
hemoglobin requiring > 2 units of red cells transfusion. One patient in the nonobese group experienced rectal bleeding. Two
patients in the obese group were documented to have experienced hematuria during that hospitalization. Overall, no major
bleeding was documented that warranted discontinuation of therapy.
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Figure 3: Achieving Goal aPTT Within 24 Hours

Figure 4: Percent of Patients’ Achieving Goal aPTT
Discussion
To our knowledge, this is the first study to evaluate the heparin weight based protocol in our institution between nonobese and
obese patients. Raschke et al compared the performance of a weight based UFH approach (80 units/kg initial bolus followed by
18 units/kg/hr infusion and adjust based on nomogram) for treatment of venous or arterial thromboembolism or for unstable
angina.4 Study results demonstrated that UFH weight based dosing was superior to the standard of practice consisting of fixed
bolus doses and infusion rate in the early 1990s.4 About 97% and 77% of patients achieved therapeutic goal within 24 hours,
respectively.4 However; Raschke et al did not stratify the data based on patients’ body weight. Mean weight in both study arms
(UFH weight based and standard UFH nomogram) were 80.9 kg and 76.9 kg, respectively.4 It was difficult to extrapolate the
results of this study to obese patients since the body mass indexes were not presented. Our study demonstrated that despite the
more conservative weight-based regimen, 72.7% obese patients and 71.3% non-obese patients achieved goal aPTT in the initial
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24 hours utilizing our heparin weight-based protocol.9 No difference was detected between both study groups within the initial 24
and 48 hours.
While evaluating major bleeding, based on the ISTH definition, a drop of  2 g/dL in hemoglobin was usually detected on day 2
of therapy. Blood products were commonly administered if hemoglobin levels dropped below 8 g/dL. It is important to mention, of
the documented bleeding episodes, none were detected in the critical areas or organs. One nonobese patient with documented
bleeding had a past medical history significant for Crohn’s Disease which can confound the bleeding events. As with results from
previous studies, no significant difference was found between nonobese and obese patient bleeding events.4,7 Lower or similar
bleeding rates (1.9% and 4.5%) were also detected compared to previous studies (5.7% and 4.5) in both nonobese and obese
patients, respectively.7
With these findings, our institution has revised the weight-based protocol. From a practice standpoint, clinical outcomes include
achieving goal aPTT sooner within the 24 hour time span while maintaining safety. The bolus dose and initial infusion rate has
been revised reflecting current recommendations from CHEST guidelines.1,8,9 However, a maximum cap still applies but has
increased to 10,000 units of heparin. With these changes, our institution plans on conducting a further study to determine safety
and if a difference in achieving goal aPTT is detected between non-obese and obese patients.
While this study demonstrates equal appropriateness between nonobese and obese patient utilizing the current therapy at our
facility, there were some limitations. This protocol was not universal among hospitals demonstrating low external validity. It would
be difficult to extrapolate our results and recommendations to other institutions. This was a non-randomized study limiting
generalization to all patients in the hospital. Many patients analyzed within 24-48 hours of therapy, did not receive therapy for the
entire 48 hours. For some, therapy was discontinued prior to achieving goal aPTT which lowers the percentage of patients
achieving goal aPTT within 48 hours. For many patients, aPTT levels were not obtained at the exact time indicated delaying the
time to adjust the infusion rate; with subtle delays, achieving aPTT levels may have been affected.
Conclusion
Overall, there was no difference in achieving goal aPTT between nonobese and obese patients while utilizing our facilities
weight- based heparin dosing. Of the study population, 71.3% of non-obese and 72.7% of obese patients achieved goal aPTT
within 24 hours. Approximately 90% of patients achieved goal aPTT within 48 hours in both the nonobese and obese group. No
major bleeding was documented that warranted discontinuation of therapy. Bleeding incidents between both groups were not
significant. Lacking a universal benchmark on timing of reaching aPTT goal, our heparin weight-based program is considered
safe and appropriate.
References
1. Garcia DA, Baglin TP, Weitz J, Samama MM. Parenteral anticoagulants: Antithrombotic therapy and prevention of
thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012
Feb;141(2 Suppl):e24s-43s. [PMID 22315264]
2. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated
partial thromboplastin time. N Engl J Med. 1972 Aug;287(7):324-7. [PMID 5041701]
3. Smith SB, Geske JB, Maguire JM, Zane NA, Carter RE, Morgenthaler TI. Early anticoagulation is associated with
reduced mortality for acute pulmonary thrombus. Chest. 2010 Jun;137(6):1382-90. doi:10.1378/chest.09-0950 [PMID
20081101]
4. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared
with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med. 1993 Nov 1;119(9):874-81. [PMID
8214998]
5. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest. 2002
Nov;25(10):899-904. [PMID 12508953]
6. Targher G, Zoppini G, Moghetti P, Day CP. Disorders of coagulation and hemostasis in abdominal obesity: Emerging
role of fatty liver. Semin Thrombo Hemost. 2010 Feb;36(1):41-8. [PMID 20391295]
7. Bauer SR, Ou NN, Dreesman BJ, Armon JJ, Anderson JA, Cha SS, Oyen LJ. Effect of body mass index on bleeding
frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: A retrospective
cohort study. Mayo Clin Proc. 2009 Dec;84(12):1073-78. [PMID 19955244]
8. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention
of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest.
2012 Feb;141(2 Suppl):e531s-75s. [PMID 22315271]

© The Internet Journal of Allied Health Sciences and Practice, 2015

Evaluation of Current Heparin Weight Based Protocol in Obese Patients

9.
10.
11.
12.
13.

7

Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic
therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines. Chest. 2012 Feb;141(2 Suppl):e152s-84s. [PMID 22315259]
Spruill WJ, Wade WE, Huckaby WG, Leslie RB. Achievement of anticoagulation by using a weight-based heparin
dosing protocol for obese and nonobese patients. Am J Health Syst Pharm. 2001 Nov;58(22):2143-46. [PMID
11760916]
Hurewitz AN, Khan SU, Groth ML, Patrick PA, Brand DA. Dosing of unfractionated heparin in obese patients with
venous thromboembolism. J Gen Intern Med. 2010 May;26(5):487-91. [PMID 21161426]
World Health Organization. Obesity and overweight. Updated January 2015.
http://www.who.int/mediacentre/factsheets/fs311/en/ Accessed August 5, 2015.
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in
non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692-4. [PMID 15842354]

© The Internet Journal of Allied Health Sciences and Practice, 2015

